Stay updated on Nivolumab Ramucirumab Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ramucirumab Combo in NSCLC Clinical Trial page.

Latest updates to the Nivolumab Ramucirumab Combo in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous funding-status notice (Revision: v3.4.1). No changes to the study data or substantive content are observed.SummaryDifference0.5%

- Check21 days agoChange DetectedGeneral site updates include a government funding notice banner at the top of the page and a revision tag showing v3.4.1; these changes do not affect the study content such as eligibility criteria or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedThe page now shows a glossary toggle in the header/footer and updates the study metadata to include Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0, while removing the older labels Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4. These are minor UI/metadata updates that do not affect core content or functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check35 days agoChange DetectedThe study status changed from Recruiting to Active, not recruiting, and enrollment was updated to 36. Study contact and investigator information was removed.SummaryDifference2%

- Check42 days agoChange DetectedRevision update from v3.3.3 to v3.3.4 with no changes to the study content, endpoints, eligibility criteria, or contact details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedLocations section updated to list study sites in New York and Pennsylvania under a single Locations section, consolidating the prior 'New York Locations' and 'Pennsylvania Locations' entries.SummaryDifference0.3%

Stay in the know with updates to Nivolumab Ramucirumab Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ramucirumab Combo in NSCLC Clinical Trial page.